Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 927 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: AdverseEvent Clear all
Terminated Phase 1Phase 2 Interventional Results available

Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis

NCT02037347
View directory record Official record
Conditions
Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome
Interventions
Palifermin
Drug
Lead sponsor
Brett King
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Bridgeport, Connecticut • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Oct 23, 2026, 9:12 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT07744126
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Telisotuzumab Adizutecan, Pembrolizumab, Carboplatin, Cisplatin, Fluorouracil
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Duarte, California • Newnan, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 23, 2026, 9:12 AM EDT
Recruiting Not applicable Interventional

Online Nutrition Education to Decrease the Side Effects of Chemotherapy in Patients With Breast Cancer

NCT05874297
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Interventions
Best Practice, Internet-Based Intervention, Questionnaire Administration
Other · Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 23, 2026, 9:12 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation the Effects of Various Treatments on RZL-012-Induced Adverse Events

NCT05476679
View directory record Official record
Conditions
Submental Fat
Interventions
RZL-012, RZL-012+Lidacaine injection prior treatment, RZL-012+Medrol, RZL-012+Celecoxib+Zyrtec, RZL-012+facial and neck wrap
Drug
Lead sponsor
Raziel Therapeutics Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Manhattan, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 23, 2026, 9:12 AM EDT
Completed Phase 4 Interventional

A Comparison Study of Kaletra Soft-Gel Capsules and Kaletra Tablets in an African American Cohort

NCT00268827
View directory record Official record
Conditions
HIV-1, AIDS
Interventions
Kaletra soft-gel capsules switched to Kaletra tablets, MOS-HIV Health and Medication Satisfaction Survey, Global Conditioning Improvement and Therapy Preference Questionnaire
Drug · Device
Lead sponsor
AIDS Arms Inc.
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2007 · Synced Oct 23, 2026, 9:12 AM EDT
Completed Not applicable Interventional

Translating ECHOS2 Into an mHealth Platform

NCT05923242
View directory record Official record
Conditions
Childhood Cancer, Cardiac Toxicity, Pediatric Cancer
Interventions
Computerized Intervention Authoring Software (CIAS)
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Oct 23, 2026, 9:12 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

PARIS or PAtch RIng Study: A Trial to Evaluate NuvaRing Versus OrthoEvra

NCT00269620
View directory record Official record
Conditions
Contraception
Interventions
ethinyl estradiol/etonogestrel vaginal ring, ethinyl estradiol/norelgestromin transdermal contraceptive
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
Female only
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
10
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2008 · Synced Oct 23, 2026, 9:12 AM EDT
Completed Not applicable Interventional Results available

PROcalcitonin Impact on Antibiotic Reduction, adverSe Events and AVoidable healthcarE Costs (ProSAVE): A RCT

NCT04158804
View directory record Official record
Conditions
Pneumonia, Bacterial
Interventions
procalcitonin
Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 110 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
6
States / cities
Torrington, Connecticut • Atlanta, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 23, 2026, 9:12 AM EDT
Completed Phase 4 Interventional Results available

The Dual Antiplatelet Therapy Study (DAPT Study)

NCT00977938
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Placebo & Aspirin, Clopidogrel & Aspirin, Prasugrel & Aspirin
Drug
Lead sponsor
Baim Institute for Clinical Research
Other
Eligibility
18 Years and older
Enrollment
25,682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
178
States / cities
Fairhope, Alabama • Gilbert, Arizona • Phoenix, Arizona + 143 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 23, 2026, 9:12 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT06236438
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Livmoniplimab, Budigalimab, Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
19
States / cities
La Jolla, California • Pembroke Pines, Florida • Winter Haven, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 23, 2026, 9:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Dose Study to Assess Adverse Events and How Oral Icalcaprant Moves Through the Body in Healthy Adult Japanese and Han Chinese Participants

NCT06722417
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Icalcaprant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 23, 2026, 9:12 AM EDT
Completed Phase 4 Interventional Results available

Study of Brain Response to Emotional Pictures Using a Magnetic Resonance Imaging (fMRI) While on Escitalopram

NCT00707863
View directory record Official record
Conditions
Major Depression
Interventions
Escitalopram
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 23, 2026, 9:12 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have

NCT05831176
View directory record Official record
Conditions
Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD), Eosinophilic Gastrointestinal Disease (EGID), Eosinophilic Gastroenteritis
Interventions
Dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
36
States / cities
Phoenix, Arizona • Apple Valley, California • La Jolla, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 23, 2026, 9:12 AM EDT
Recruiting Phase 1 Interventional

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT05650632
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Etentamig (ABBV-383)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
27
States / cities
Phoenix, Arizona • Springdale, Arkansas • Aurora, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 23, 2026, 9:12 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan

NCT07196644
View directory record Official record
Conditions
Solid Tumors Harboring MET Amplification
Interventions
Telisotuzumab Adizutecan
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
18
States / cities
Beverly Hills, California • Duarte, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 23, 2026, 9:12 AM EDT
Not listed Phase 2 Interventional

Evaluate the Side Effects and Benefits of RAS 130 With or Without Diet and Exercise in Type II Diabetes Mellitus

NCT00737152
View directory record Official record
Conditions
Type II Diabetes Mellitus
Interventions
RAS 130 with diet and exercise
Other
Lead sponsor
American Scitech International
Other
Eligibility
30 Years to 60 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
East Brunswick, New Jersey • New Brunswick, New Jersey • Perth Amboy, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Oct 23, 2026, 9:12 AM EDT
Completed Phase 3 Interventional

Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer

NCT00006481
View directory record Official record
Conditions
Head and Neck Cancer, Skin Reactions Secondary to Radiation Therapy
Interventions
Biafine cream, quality-of-life assessment, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
0 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
240
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 187 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 23, 2026, 9:12 AM EDT
Terminated Not applicable Interventional Results available

Determining the Impact of a Medication Delivery Unit on Medication Adherence of Adults With Common Cardiac Conditions

NCT01600677
View directory record Official record
Conditions
Medication Adherence, Medication Nonadherence, Adverse Reaction to Drug
Interventions
Computerized medication delivery unit, Usual care
Device · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 26, 2016 · Synced Oct 23, 2026, 9:12 AM EDT
Completed No phase listed Observational

Effectiveness of an ADE-related Hospitalization Risk Prediction Tool for Patients (ADE-RED)

NCT04181775
View directory record Official record
Conditions
Adverse Drug Event
Interventions
ADE-RED scoring tool
Diagnostic Test
Lead sponsor
Methodist Health System
Other
Eligibility
Not listed
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 23, 2026, 9:12 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Comparison of Infection Rates Between Two Surgical Sites

NCT01263262
View directory record Official record
Conditions
Corneal Toxicity, Ototoxicity, Surgical Site Infection
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 24, 2013 · Synced Oct 23, 2026, 9:12 AM EDT
Completed No phase listed Observational Results available

A Feasibility Study Followed By A Randomized Phase II Study Of Yoga For Radiation Therapy Side Effects In Prostate Cancer

NCT02135653
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiotherapy, Eischens Yoga
Radiation · Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 23, 2026, 9:12 AM EDT
Not listed No phase listed Observational

Complications and Adverse Events in Lymphadenectomy in the Inguinal Area

NCT05388786
View directory record Official record
Conditions
Consensus Development
Interventions
Delphi Questionnaire
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Oct 23, 2026, 9:12 AM EDT
Active, not recruiting Phase 2 Interventional

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)

NCT06632951
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Livmoniplimab, Budigalimab, Docetaxel, Paclitaxel, Gemcitabine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
11
States / cities
Springdale, Arkansas • San Francisco, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 23, 2026, 9:12 AM EDT
Completed Phase 3 Interventional Results available

Prevention of Serious Adverse Events Following Angiography

NCT01467466
View directory record Official record
Conditions
Acute Renal Failure, Kidney Disease, Coronary Artery Disease
Interventions
IV isotonic saline, IV isotonic bicarbonate, N-acetylcysteine, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
5,177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
35
States / cities
Tucson, Arizona • Little Rock, Arkansas • Palo Alto, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 23, 2026, 9:12 AM EDT